Hong Kong Consumer Services Stock News

K. H. Group Holdings Limited ( HKG:1557 ) shares have continued their recent momentum with a 32% gain in the last month...

China Digital Video Holdings Limited ( HKG:8280 ) shareholders that were waiting for something to happen have been...

It's not a stretch to say that China BlueChemical Ltd.'s ( HKG:3983 ) price-to-earnings (or "P/E") ratio of 10.6x right...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Key Insights The projected fair value for China In-Tech is HK$0.94 based on 2 Stage Free Cash Flow to Equity China...

Despite an already strong run, China New Energy Limited ( HKG:1156 ) shares have been powering on, with a gain of 27...

Texhong International Group Limited ( HKG:2678 ) shares have continued their recent momentum with a 27% gain in the...

Jiu Rong Holdings Limited ( HKG:2358 ) shares have had a really impressive month, gaining 45% after a shaky period...

Hop Fung Group Holdings Limited ( HKG:2320 ) shareholders won't be pleased to see that the share price has had a very...

Insiders who bought Bonjour Holdings Limited ( HKG:653 ) in the last 12 months may probably not pay attention to the...

Last week, Wisdomcome Group Holdings Limited's (HKG:8079) stock jumped 11%, but insiders who sold HK$3.7m worth of...

Pokfulam Development Company Limited's ( HKG:225 ) investors are due to receive a payment of HK$0.32 per share on 6th...

Key Insights Significant control over First Pacific by individual investors implies that the general public has more...

As global markets navigate a landscape of steady interest rates and fluctuating consumer confidence, investors are increasingly looking toward emerging opportunities in Asia. Penny stocks, often considered relics of past market eras, continue to hold potential when supported by strong financial fundamentals. This article highlights several noteworthy penny stocks that combine affordability with promising growth prospects, offering investors a chance to explore under-the-radar companies with...

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

Tax jitters and AI promotions put Tencent in focus Interest in Tencent Holdings (SEHK:700) has picked up after a sharp selloff in Chinese tech stocks tied to possible higher value added taxes on internet firms, alongside Tencent's cash giveaways promoting its Yuanbao AI app. See our latest analysis for Tencent Holdings. The recent selloff in Chinese tech, combined with Tencent's Yuanbao promotions and fresh competition around AI giveaways, has contributed to a 30 day share price return of an...

Everest Medicines (SEHK:1952) has signed an exclusive license agreement to commercialize MT1013 for secondary hyperparathyroidism in China and the broader Asia Pacific region. MT1013 is entering Phase III trials, with development expenses covered by Everest Medicines' partner under the deal. The agreement expands the company’s renal pipeline and commercial portfolio, targeting unmet medical needs in kidney related complications. Everest Medicines, trading at HK$38.86, has seen mixed share...

What the new Tianqi Grand Vision Energy agreement means for Envision Greenwise Envision Greenwise Holdings (SEHK:1783) has entered a new framework agreement with Tianqi Grand Vision Energy, covering lithium ion battery recycling R&D, potential cross equity investment, black mass supply, and overseas expansion starting from Hong Kong. See our latest analysis for Envision Greenwise Holdings. At a share price of HK$3.21, Envision Greenwise has recently seen a 7 day share price return of 5.31%...

WuXi Biologics (Cayman) (SEHK:2269) announced new alliances with Vertex Pharmaceuticals and Sinorda Biomedicine for co-development and manufacturing of biologics targeting autoimmune diseases. The company also expanded its agreement with HanchorBio to cover next generation fusion protein programs. Together, these collaborations broaden WuXi Biologics' role as a global contract research, development and manufacturing partner across multiple therapeutic modalities. WuXi Biologics focuses on...

New World Development has been cleaning up its balance sheet through debt reduction and asset sales in recent months, aiming to sharpen its focus on core businesses. An interesting angle for investors is how this ongoing restructuring could reframe perceptions of a highly leveraged Hong Kong developer at a time of weak sector sentiment. We’ll now examine how New World Development’s balance sheet restructuring effort shapes its broader investment narrative for investors assessing long-term...

Bank of Qingdao (SEHK:3866) has drawn fresh attention after reporting full year 2025 earnings, with net income of CN¥5,187.74 million and basic EPS from continuing operations of CN¥0.85. See our latest analysis for Bank of Qingdao. The earnings release comes after a strong run in the shares, with a 16.23% year to date share price return and a 53.50% total shareholder return over the past year, suggesting momentum has been building rather than fading. If Bank of Qingdao’s recent move has you...

Simcere Pharmaceutical Group (SEHK:2096) has drawn investor attention after announcing an exclusive licensing agreement with Boehringer Ingelheim for SIM0709, a TL1A/IL-23p19 bispecific antibody targeting inflammatory bowel disease. See our latest analysis for Simcere Pharmaceutical Group. The licensing news arrives after a mixed year in the market, with Simcere’s 1-year total shareholder return of 77.9% contrasting with a year to date share price return of 0.85% and a 90 day share price...

In late January 2026, China Galaxy Securities Co., Ltd. completed two fixed-income offerings totaling CNY 6.0 billion, issuing 1.85% notes due 2029 and 1.79% notes due 2028 at 100% of face value, both as non-convertible corporate bonds with fixed coupons. These bond completions followed China Securities Regulatory Commission approval for China Galaxy Securities to register and issue up to CNY 20.00 billion in subordinated bonds to professional investors, expanding its funding options and...

BYD (SEHK:1211) is back in focus after reporting a 30% year on year drop in January sales to about 210,000 vehicles, its fifth straight monthly decline, which coincided with weaker government incentives. See our latest analysis for BYD. The weak January sales and reduced incentives have come after a tough spell for the shares, with a 7 day share price return of 10.36% and a 1 month share price return of 8.01%, leaving the share price at HK$91.25. Even so, the 1 year total shareholder return...